调控性ChREBP/14-3-3复合物的分子剂保护β细胞免受葡萄糖脂毒性影响
Liora S Katz1, Emira J Visser2, Kathrin F Plitzko3
1Diabetes, Obesity and Metabolism Institute and Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nature communications
|March 2, 2025
概括
科学家们开发出一种新的分子,以稳定蛋白质相互作用,保护人类β细胞免受损伤,在2型糖尿病模型中. 这种方法为糖尿病治疗提供了一个新的治疗策略.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 内分泌学 在内分泌学.
背景情况:
- 转录因子ChREBP (碳水化合物反应元素结合蛋白) 调节葡萄糖的新陈代谢.
- 通过14-3-3结合抑制ChREBPα活性,导致细胞质保留.
- 对ChREBP的失调有助于2型糖尿病中的β细胞功能障碍.
研究的目的:
- 开发稳定ChREBPα/14-3-3蛋白与蛋白相互作用 (PPI) 的小分子.
- 评估ChREBPα/14-3-3 PPI稳定剂在保护β细胞免受葡萄糖脂毒性的治疗潜力.
主要方法:
- "分子"化合物的基于结构的设计和优化.
- 在体外和细胞模型中评估化合物在稳定ChREBPα/14-3-3 PPI中的活性.
- 在葡萄糖脂质毒性条件下评估化合物对人类初级β细胞的影响.
主要成果:
- 优化的"分子"化合物证明了对ChREBPα/14-3-3 PPI的强有力的稳定.
- 最活跃的化合物有效地在人类β细胞的细胞质中保留了ChREBPα.
- 这种化合物显著地保护β细胞免受葡萄糖脂毒性诱导的损伤,并保留β细胞的身份.
结论:
- ChREBPα/14-3-3 PPI的小分子稳定是一种可行的2型糖尿病治疗策略.
- 这项研究提出了一种新的"分子"方法来准转录因子.
- 开发的化合物为治疗2型糖尿病提供了潜在的新类药物.
相关概念视频
Cell Specific Gene Expression
13.4K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
13.4K
Hormones Regulating Blood Glucose
3.0K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.0K
Insulin Secretory Vesicles
4.8K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
4.8K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.0K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.0K
Protein Folding Quality Check in the RER
3.7K
ER is the primary site for the maturation and folding of soluble and transmembrane secretory proteins. The calnexin cycle is a specific chaperone system that folds and assesses the confirmation of N-glycosylated proteins before they can exit the ER lumen. The primary players of this quality check pipeline are the lectins, ER-resident chaperones, and a glucosyl transferase enzyme. In case the calnexin system in the lumen fails to salvage a misfolded protein, it is transported to the cytoplasm...
3.7K
Glucagon-like Receptor Agonists
290
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
290


